Monthly Communication Report

Corporation:	AstraZeneca Canada Inc.
Associated registration:	957438-15042-64
Communication date:	2026-02-10
Posted date:	2026-03-16

Designated Public Office Holders who participated in the communication:	Mark Szeto, Policy Analyst NIHB, Indigenous Services Canada (ISC) Bradley Bennet, Pharmacist NIHB, Indigenous Services Canada (ISC) Karen Fortin, Director, Pharmacy Benefits NIHB, Indigenous Services Canada (ISC) Peter Berry, Senior Policy Analyst and Science Advisor NIHB, Indigenous Services Canada (ISC) Dylan Radke, Pharmacist NIHB, Indigenous Services Canada (ISC) Michelle Mujoombar, Manager NIHB, Indigenous Services Canada (ISC)
List of Details Subject matter Detail Aboriginal Affairs, Government Procurement, Health Federally-funded Public Drug Plans, including the Non Insured Health Benefits program, with respect to reimbursement for drug products for beneficiaries. Economic Development, Federal-Provincial Relations, Health, Industry, Intellectual Property, Research and Development Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Responsible Officer who filed this communication report:	Gaby Bourbara
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.